#alxn

Alexion Pharmaceuticals, (ALXN): Q3 2019 Earnings Snapshot

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected.

Revenues grew 23% to $1.26 billion, vs. $1.24 billion expected. Sales of SOLIRIS (eculizumab) came in at $990.5 million, up 12% year-over-year.

Raised FY19 revenue guidance to $4.86 – $4.89 billion vs. prior guidance of $4.75 – $4.8 billion billion.

Adjusted EPS…

Earnings: Alexion Pharma Q2 results top expectations; raises FY19 guidance

Alexion Pharmaceuticals (Nasdaq: ALXN) reported a 28% increase in second-quarter earnings, helped by growth in revenues. The results also topped the Street view. The company revised up its full-year revenue guidance.

Second-quarter revenues moved up 15% to $1.20 billion from the same period of last year and came in above analysts’ forecast.

The New Haven, Connecticut-based pharma…

Motley Fool: 3 Biotech Stocks That Could Double Your Money

Doubling your money in the stock market really isn’t that hard if you don’t mind waiting. For example, a sum invested in the S&P 500 six years ago would have doubled already.

For those of you interested in a shorter time frame there are a few biotech stocks that recently received some highly favorable coverage from Wall Street investment banks. 

Image source: Getty Images.

Blindly following…

Motley Fool: 4 Blockbuster Drug Launches to Watch in 2019

Get ready for some blockbuster drug launches that could get intense. 

Clarivate Analytics has offered a report on experimental drugs entering the market soon that are expected to generate sales above $1 billion in 2023. Every potential blockbuster is important to the company that launches it, but there are a few in the annual Clarivate report that are more important than usual. In 2019, AbbVie (

Dropping The 52 Week Low, Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) Closing At $101.22

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN)

December 20th, 2018 Amidst falling markets Alexion Pharmaceuticals, Inc. finished Thursday’s trading session down 1.52%, a $1.56 decrease to close on $101.22. As well as the drop in value, Alexion Pharmaceuticals, Inc. hit a new 52 week low of $99.75, breaking the previous low of $100.93 from earlier this month. Despite the drop in value, trading…

Nasdaq 100 Movers: ALXN, ADBE

Nov 28, 2018 (MarketNewsVideo.com via COMTEX) —

In early trading on Wednesday, shares of Adobe topped the list of the day’s best performing components of the Nasdaq 100 index, trading up 4.0%. Year to date, Adobe registers a 37.8% gain.

And the worst performing Nasdaq 100 component thus far on the day is Alexion Pharmaceuticals, trading down 2.4%. Alexion Pharmaceuticals is lower by about…

$ALXN 2018-10-24 : Transcripts- ALXN Edited Transcript of ALXN earnings conference call

Get Transcripts on your mobile as soon as they are released. Download the Android App below

[s2If !current_user_can(access_s2member_level0)] Please login to read the transcript. [lwa] [/s2If][s2If current_user_can(access_s2member_level0)]”

Q3 2018 Alexion Pharmaceuticals Inc Earnings Call

CHESHIRE Oct 25, 2018 (Thomson StreetEvents) — Edited Transcript of Alexion Pharmaceuticals Inc…

$ALXN 2018-10-24 : Transcripts- Edited Transcript of ALXN earnings conference call

Get Transcripts on your mobile as soon as they are released. Download the Android App below

[s2If !current_user_can(access_s2member_level0)] Please login to read the transcript. [lwa] [/s2If][s2If current_user_can(access_s2member_level0)]”

Q3 2018 Alexion Pharmaceuticals Inc Earnings Call

CHESHIRE Oct 25, 2018 (Thomson StreetEvents) — Edited Transcript of Alexion Pharmaceuticals Inc…